Clinical trial

Psilocybin Therapy for Depression in Bipolar II Disorder

University of California, San FranciscoActive, not recruitingPhase 2Started Jan 28, 202214 enrolledUnited StatesNCT05065294

Abstract

The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy in people with Bipolar II Disorder.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

PsilocybinDepression

Keywords

BipolarPsychedelicPsilocybin TherapyBipolar IISafetyBipolar II Disorder

View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticlePsilocybin

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

Carhart-Harris RL, Bolstridge M, Day CMJ +13

Europe PMC2018

ArticlePsilocybin

An Open-Label, Dose-Escalation Trial of Psilocybin-Assisted Therapy for Bipolar II Depression.

Downey AE, Szigeti B, Bradley ER +11

Europe PMC2026

Related research

ArticlePsilocybin

Association of Psilocybin Use in Adolescents with Major Depressive Episode

Shah K, Trivedi C, Kamrai D +2

Europe PMC2022

ArticlePsilocybin

Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.

Haridy R

Europe PMC2023

ArticlePsilocybin

Cystathionine Gamma-Lyase Regulate Psilocybin Biosynthesis in <i>Gymnopilus dilepis</i> Mushroom via Amino Acid Metabolism Pathways.

Yao S, Wei C, Lin H +5

Europe PMC2022